Targeting breast cancer stem cells with ellipticine
2013
National Institute of Pathology, New Delhi, India
Breast cancer stem cells are surging as a potential target to disrupt cancer progression and avoid further relapses. Here, the effects of ellipticine on ALDH1A1-expressing human breast cancer stem cells are studied both in in vitro and in silico setups. The results show that at concentrations of 3mM it was able to significantly decrease the ALDH1A1+ cancer stem cells in two different human breast cancer cell lines. Contrary to paclitaxel, ellipticine also reduced mammosphere formation but, when both agents were combined, there was an enormous drop of ALDH1A1+ cancer stem cells. The in silico model revealed that several residues of ALDH1A1 were potentially interacting with ellipticine, confirming the potential interactions of the drug with this protein. In this study, the researchers demonstrate that ellipticine can disrupt the proliferation abilities of ALDH1A1+ breast cancer stem cells and can be combined with cytotoxic therapeutical agents to efficiently target them.
Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells—an in vitro and in silico study
Sunita Saxena
Added on: 10-14-2021
[1] https://link.springer.com/article/10.1007/s13277-013-1099-y[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
